MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.
MOR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for MorphoSys AG. To summarize, we found that MorphoSys AG ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. As for the metrics that stood out in our discounted cash flow analysis of MorphoSys AG, consider:
The company's balance sheet shows it gets 58% of its capital from equity, and 42% of its capital from debt. Its equity weight surpasses that of just 20.5% of free cash flow generating stocks in the Healthcare sector.
The company's compound free cash flow growth rate over the past 0.25 years comes in at -0.71%; that's greater than just 0.98% of US stocks we're applying DCF forecasting to.
MorphoSys AG's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 13.55% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of MorphoSys AG? See AGHC, AHPI, ALC, AMRN, and DRAD.
MorphoSys AG (MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participants Jason Butler - JMP Securities...
MorphoSys' Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.
The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 14, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today that its licensee Janssen Research & Development, ...